Literature DB >> 27528663

Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.

Yubao Wang1, Michael Begley2, Qing Li1, Hai-Tsang Huang1, Ana Lako1, Michael J Eck1, Nathanael S Gray1, Timothy J Mitchison3, Lewis C Cantley4, Jean J Zhao5.   

Abstract

The protein kinase maternal and embryonic leucine zipper kinase (MELK) is critical for mitotic progression of cancer cells; however, its mechanisms of action remain largely unknown. By combined approaches of immunoprecipitation/mass spectrometry and peptide library profiling, we identified the eukaryotic translation initiation factor 4B (eIF4B) as a MELK-interacting protein during mitosis and a bona fide substrate of MELK. MELK phosphorylates eIF4B at Ser406, a modification found to be most robust in the mitotic phase of the cell cycle. We further show that the MELK-eIF4B signaling axis regulates protein synthesis during mitosis. Specifically, synthesis of myeloid cell leukemia 1 (MCL1), an antiapoptotic protein known to play a role in cancer cell survival during cell division, depends on the function of MELK-elF4B. Inactivation of MELK or eIF4B results in reduced protein synthesis of MCL1, which, in turn, induces apoptotic cell death of cancer cells. Our study thus defines a MELK-eIF4B signaling axis that regulates protein synthesis during mitosis, and consequently influences cancer cell survival.

Entities:  

Keywords:  MCL1; MELK; eIF4B; mitosis; protein synthesis

Mesh:

Substances:

Year:  2016        PMID: 27528663      PMCID: PMC5024598          DOI: 10.1073/pnas.1606862113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Rapid turnover of mcl-1 couples translation to cell survival and apoptosis.

Authors:  Kenneth W Adams; Geoffrey M Cooper
Journal:  J Biol Chem       Date:  2007-01-02       Impact factor: 5.157

2.  Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.

Authors:  B D Li; L Liu; M Dawson; A De Benedetti
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

3.  Regulation of protein synthesis in mammalian cells. II. Inhibition of protein synthesis at the level of initiation during mitosis.

Authors:  H Fan; S Penman
Journal:  J Mol Biol       Date:  1970-06-28       Impact factor: 5.469

4.  The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Authors:  Bo Cen; Ying Xiong; Jin H Song; Sandeep Mahajan; Rachel DuPont; Kristen McEachern; Daniel J DeAngelo; Jorge E Cortes; Mark D Minden; Allen Ebens; Alice Mims; Amanda C LaRue; Andrew S Kraft
Journal:  Mol Cell Biol       Date:  2014-04-28       Impact factor: 4.272

5.  A region rich in aspartic acid, arginine, tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B (eIF4B) self-association and interaction with eIF3.

Authors:  N Méthot; M S Song; N Sonenberg
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

6.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

8.  AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B.

Authors:  A G M van Gorp; K E van der Vos; A B Brenkman; A Bremer; N van den Broek; F Zwartkruis; J W Hershey; B M T Burgering; C F Calkhoven; P J Coffer
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

9.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Regulation of mRNA translation during mitosis.

Authors:  Marvin E Tanenbaum; Noam Stern-Ginossar; Jonathan S Weissman; Ronald D Vale
Journal:  Elife       Date:  2015-08-25       Impact factor: 8.140

View more
  31 in total

1.  Arrestin-3 interaction with maternal embryonic leucine-zipper kinase.

Authors:  Nicole A Perry; Kevin P Fialkowski; Tamer S Kaoud; Ali I Kaya; Andrew L Chen; Juliana M Taliaferro; Vsevolod V Gurevich; Kevin N Dalby; T M Iverson
Journal:  Cell Signal       Date:  2019-07-25       Impact factor: 4.315

2.  Mammalian cell growth dynamics in mitosis.

Authors:  Teemu P Miettinen; Joon Ho Kang; Lucy F Yang; Scott R Manalis
Journal:  Elife       Date:  2019-05-07       Impact factor: 8.140

3.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

4.  Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.

Authors:  Blake S Moses; Samantha McCullough; Jennifer M Fox; Bryan T Mott; Søren M Bentzen; MinJung Kim; Jeffrey W Tyner; Rena G Lapidus; Ashkan Emadi; Michelle A Rudek; Tami J Kingsbury; Curt I Civin
Journal:  Blood Adv       Date:  2021-02-09

Review 5.  Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.

Authors:  Jue Shi; Timothy J Mitchison
Journal:  Endocr Relat Cancer       Date:  2017-03-01       Impact factor: 5.678

6.  Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.

Authors:  Kyle C Arend; Erik M Lenarcic; Heather A Vincent; Naim Rashid; Eric Lazear; Ian M McDonald; Thomas S K Gilbert; Michael P East; Laura E Herring; Gary L Johnson; Lee M Graves; Nathaniel J Moorman
Journal:  Mol Cell Proteomics       Date:  2017-02-25       Impact factor: 5.911

7.  Computational insights into the binding of IN17 inhibitors to MELK.

Authors:  Matthew Harger; Ju-Hyeon Lee; Brandon Walker; Juliana M Taliaferro; Ramakrishna Edupuganti; Kevin N Dalby; Pengyu Ren
Journal:  J Mol Model       Date:  2019-05-08       Impact factor: 1.810

8.  MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway.

Authors:  Radoslav Janostiak; Navin Rauniyar; TuKiet T Lam; Jianhong Ou; Lihua J Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

9.  Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.

Authors:  Ian M McDonald; Gavin D Grant; Michael P East; Thomas S K Gilbert; Emily M Wilkerson; Dennis Goldfarb; Joshua Beri; Laura E Herring; Cyrus Vaziri; Jeanette Gowen Cook; Michael J Emanuele; Lee M Graves
Journal:  J Biol Chem       Date:  2020-01-02       Impact factor: 5.157

10.  Small-molecule modulators of INAVA cytosolic condensate and cell-cell junction assemblies.

Authors:  Denis Chang; Phi Luong; Qian Li; Jamie LeBarron; Michael Anderson; Lee Barrett; Wayne I Lencer
Journal:  J Cell Biol       Date:  2021-07-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.